Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009

FARMINGDALE, N.Y., May 11 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq:
MSON), a developer of minimally invasive ultrasonic medical device technology,
which in Europe is used for the ablation of tumors and worldwide for other
acute health conditions, today reported financial results for the three and
nine months ended March 31, 2009. Michael A. McManus, Jr., President and
Chief Executive Officer, and Richard Zaremba, Senior VP and Chief Financial
Officer, will host a conference call Tuesday, May 12, 2009 at 4:30 pm to
discuss the Company's third fiscal quarter and nine months financial results.

The Company also reported the following financial and operational
achievements:
-- $.02 diluted earnings per share, for the three months ended March 31,
2009.
-- $.09 diluted earnings per share, for the nine months ended March 31,
2009.
-- Received $3.5 million in cash on April 7, 2009 after closing a
transaction for the sale of our Ultrasonics laboratory product line.

-- Executed distribution agreement in Portugal for the SonicOne
Ultrasonic
Wound Debridement System, Sonastar Ultrasonic Surgical Aspirator and
BoneScalpel Ultrasonic Bone Cutter.

Revenues for the three months ended March 31, 2009 were $8.0 million, a $2.7
million decrease when compared with revenues of $10.7 million for three months
ended March 31, 2008. The decrease in revenues for the three months ended
March 31, 2009 was due to a $1.7 million decrease in medical product device
sales to $4.8 million and a decrease in laboratory and scientific product
sales of $977,000 to $3.2 million. The decrease in sales of medical device
products was primarily attributable to lower sales of the Company's
Neuroaspirator product, the Lysonix Ultrasonic Assisted Liposuction product,
OEM probe sales and MRI repairs, partially offset by an increase in the Bone
Scalpel and SonicOne Wound Debridement Systems. The decrease in laboratory
and scientific product sales was primarily due to the strengthening of the
U.S. Dollar against the English Pound during the three months ended March 31,
2009 as compared to the three months ended March 31, 2008, reducing Labcaire
sales reported in U.S. Dollars by approximately $1.0 million.

The Company reported net income for the third quarter of fiscal 2009, of
$115,000 or $.02 diluted earnings per share compared with a net loss of
$194,000 or $.03 loss per share for the same period in fiscal 2008.

Revenues for the nine months ended March 31, 2009 were $29.3 million, a $1.3
million decrease when compared with revenues of $30.6 million for the nine
months ended March 31, 2008. The decrease in revenues for the nine months
ended March 31, 2009 was due to a $614,000 decrease in medical device product
sales to $17.2 million and a decrease in laboratory and scientific product
sales of $650,000 to $12.1 million. The decrease in sales of medical device
products was primarily attributable to lower sales of the Company's
Neuroaspirator product, Lysonix Ultrasonic Assisted Liposuction product,
Lithotripsy product, OEM probe sales and API tank and Subsystem sales. The
decrease in laboratory and scientific sales was primarily attributable to the
strengthening of the U.S. Dollar against the English Pound during the nine
months ended March 31, 2009 as compared to the three months ended March 31,
2008, reducing sales reported in U.S. Dollars by approximately $2.3 million.

The Company reported net income for the nine months ended March 31, 2009, of
$629,000 or $.09 diluted earnings per share compared with a net loss of
$537,000 or $.08 loss per share for the same period in fiscal 2008.

On April 7, 2009, Misonix, Inc. sold the assets of its Ultrasonic laboratory
product business to iSonix LLC, a wholly owned subsidiary of Sonics and
Materials, for a cash payment of $3.5 million. The Ultrasonics laboratory
business manufactures and sells ultrasonic processors (Sonicators), ultrasonic
soldering instruments, ultrasonic cleaners and related accessories. The
assets are classified as held for sale and the results of operations are
reported in discontinued operations as of March 31, 2009.

Commenting on Misonix's financial and operating results, Michael A. McManus,
Jr., President and Chief Executive Officer, said, "Our third quarter results,
particularly in our medical device business, were negatively impacted by the
worldwide economic conditions which adversely affected the demand for capital
equipment. Although the economic environment remains challenging we are
encouraged by the performance and strength of our business model. Our focus
for the remainder of the year is to build on our growing global distribution
presence for our medical device products and deliver improved results.

Looking ahead, we anticipate that fiscal 2010 will continue to be a
challenging environment, but we remain encouraged by customer response to our
new products. In addition, the cost reduction actions already taken will
continue to benefit our profitability. We believe that our new products, past
cost control efforts, and continued efficiency gains will allow us to offset
marketplace challenges.

During the quarter, we continued to execute on our initiative to significantly
expand our distribution relationships throughout the world for our innovative
Neuroaspirator, Wound Debrider and Bone Scalpel devices. We believe these
relationships will increase our medical device revenue going forward.

A key objective of the third quarter and the fiscal year is an expansion of
our European "fee for service" business model for HIFU (High Intensity Focused
Ultrasound) treatments for prostate tumors using the Sonablate(R) SB500
acoustic ablation system. We continue to meet with success in the United
Kingdom, Portugal, France and Italy, and are expecting further geographic
expansion during quarter four and the coming fiscal year.

In early April, we announced the sale of a non-core asset for $3.5 million in
cash. This transaction strengthens our balance sheet and illustrates the
underlying value of our businesses that are not reflected in our market
capitalization today. It also emphasizes our commitment to continue our
growth initiatives to become a focused medical device company."

Conference Call

Misonix management will host a conference call and webcast on Tuesday, May 12,
2009 at 4:30 pm ET to discuss the Company's third quarter fiscal 2009
financial results.

The conference call will be broadcast live via the Investor Relations section
of the Company's Web site at www.misonix.com. Alternatively, participants may
join the conference call by dialing (800) 510-0146 (domestic) or (617)
614-3449 (international) and entering access code 82240049, a few minutes
before the start of the call.

For those unable to attend the live results broadcasts, a recording of the
live-call will be available approximately 2 hours after the event through May
19, 2009. The dial-in number to listen to the recording is (888) 286-8010 or
(617) 801-6888. The replay access code is 76910719. The call will also be
archived on the Company's website for at least 90 days.

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets
therapeutic ultrasonic medical devices and laboratory equipment. Misonix's
therapeutic ultrasonic platform is the basis for several innovative medical
technologies. Addressing a combined market estimated to be in excess of $3
billion annually; Misonix's proprietary ultrasonic medical devices are used
for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery,
and other surgical and medical applications. Additional information is
available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release,
content herein may contain "forward-looking statements" that are made pursuant
to the Safe Harbor Provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based on management's current expectations and
are subject to uncertainty and changes in circumstances. Investors are
cautioned that forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from the statements made.
These factors include general economic conditions, delays and risks associated
with the performance of contracts, risks associated with international sales
and currency fluctuations, uncertainties as a result of research and
development, acceptable results from clinical studies, including publication
of results and patient/procedure data with varying levels of statistical
relevancy, risks involved in introducing and marketing new products, potential
acquisitions, consumer and industry acceptance, litigation and/or court
proceedings, including the timing and monetary requirements of such
activities, the timing of finding strategic partners and implementing such
relationships, regulatory risks including approval of pending and/or
contemplated 510(k) filings, the ability to achieve and maintain profitability
in the Company's business lines, and other factors discussed in the Company's
Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K. The Company disclaims any obligation to update
its forward-looking relationships.

MISONIX, INC. And Subsidiaries
Consolidated Balance Sheets

Derived from audited
Unaudited financial statements
March 31, 2009 June 30, 2008

Assets
------
Current Assets:
Cash $1,096,677 $1,873,863
Accounts receivable, net of
allowance for doubtful accounts
of $473,314 and $376,998,
respectively 6,245,861 7,986,802
Inventories, net 10,017,066 11,906,091
Deferred income taxes 1,125,846 1,562,279
Prepaid expenses and other
current assets 1,157,893 904,737
Current assets held for sale 622,372 745,473
---------- ----------
Total current assets 20,265,715 24,979,245

Property, plant and
equipment, net 2,984,281 4,371,373
Deferred income taxes 819,269 1,280,217
Goodwill 5,713,034 5,784,542
Other assets 1,486,551 807,203
Assets held for sale 25,255 27,494
----------- -----------
Total assets $31,294,105 $37,250,074
=========== ===========

Liabilities and
stockholders' equity
---------------------
Current liabilities:
Revolving credit facilities $2,816,852 $4,470,389
Notes payable 388,410 246,888
Accounts payable 3,344,840 5,497,541
Accrued expenses and other
current liabilities 2,868,804 4,760,115
Foreign income taxes payable 546,775 696,791
Current portion of deferred gain
from sale and leaseback of
building 113,418 159,195
Current maturities of
capital lease obligations 209,156 307,325
------- -------
Total current liabilities 10,288,255 16,138,244

Capital lease obligations 32,353 225,909
Deferred lease liability 292,999 348,502
Deferred income taxes 687,526 250,514
Deferred gain from sale and
leaseback of building 822,277 1,273,772
Deferred income 350,773 371,452
------- -------
Total liabilities 12,474,183 18,608,393

Commitments and contingencies

Minority interest 236,107 199,237

Stockholders' equity:
Capital stock, $0.01 par value
- shares authorized 20,000,000;
7,079,169 issued and 7,001,369
outstanding 70,792 70,792
Additional paid-in capital 25,193,939 25,052,539
Accumulated deficit (6,001,199) (6,630,170)
Accumulated other comprehensive
(loss) income (267,293) 361,707
Treasury stock, 77,800 shares (412,424) (412,424)
-------- --------
Total stockholders' equity 18,583,815 18,442,444
---------- ----------

Total liabilities and
stockholders' equity $31,294,105 $37,250,074
=========== ===========

MISONIX, INC. And Subsidiaries
Consolidated Statements of Operations
Unaudited

Three Months Ended Nine Months Ended
March 31, March 31,
2009 2008 2009 2008
---- ---- ---- ----
Net sales $8,047,051 $10,700,621 $29,325,347 $30,588,650

Cost of goods sold 4,743,033 6,143,723 17,474,066 17,009,968
--------- --------- ---------- ----------

Gross profit 3,304,018 4,556,898 11,851,281 13,578,682

Selling expenses 1,203,821 1,883,948 4,429,295 5,273,525
General and
administrative
expenses 2,098,672 2,470,147 6,949,336 7,596,223
Research and development
expenses 574,181 653,372 1,896,370 2,175,713
Litigation expenses 2,000 - 102,000 -
--------- --------- --------- ---------

Total operating
expenses 3,878,674 5,007,467 13,377,001 15,045,461
--------- --------- ---------- ----------

Operating loss from
continuing operations (574,656) (450,569) (1,525,720) (1,466,779)

Total other income 75,542 73,170 1,581,107 137,950
------ ------ --------- -------

Income (loss) from
continuing operations
before minority interest
and income taxes (499,114) (377,399) 55,387 (1,328,829)

Minority interest in net
(loss) income of
consolidated
subsidiaries (3,361) 24,269 32,967 47,580
------ ------ ------ ------

Income (loss) from
continuing operations
before income taxes (495,753) (401,668) 22,420 (1,376,409)

Income tax benefit (473,838) (97,266) (234,679) (381,004)
-------- ------- -------- --------

Net income (loss) from
continuing operations ($21,915) ($304,402) $257,099 ($995,405)

Net income from
discontinued operations,
net of tax $137,382 $110,365 $371,872 $457,924

Net income (loss) $115,467 ($194,037) $628,971 ($537,481)

Net income (loss) per
share from continuing
operations-basic $0.00 ($0.04) $0.04 ($0.14)
===== ====== ===== ======

Net income per share from
discontinued
operations-basic $0.02 $0.02 $0.05 $0.07
===== ===== ===== =====

Net income (loss) per
share-basic $0.02 ($0.03) $0.09 ($0.08)
===== ====== ===== ======

Net income (loss) per
share from continuing
operations-diluted $0.00 ($0.04) $0.04 ($0.14)
===== ====== ===== ======

Net income per share from
discontinuing
operations-diluted $0.02 $0.02 $0.05 $0.07
===== ===== ===== =====

Net income (loss) per
share-diluted $0.02 ($0.03) $0.09 ($0.08)
===== ====== ===== ======

Weighted average
common shares
outstanding-basic 7,001,369 7,001,369 7,001,369 7,001,369
========= ========= ========= =========

Weighted average
common shares
outstanding-diluted 7,001,369 7,001,369 7,016,299 7,001,369
========= ========= ========= =========

Investor Relations Contact:
Kevin McGrath
Cameron Associates, Inc.
212-245-4577
Kevin@cameronassoc.com

SOURCE Misonix, Inc.

Richard Zaremba of Misonix, +1-631-694-9555, invest@misonix.com, or Investor
Relations, Kevin McGrath of Cameron Associates, Inc., +1-212-245-4577,
Kevin@cameronassoc.com